%0 Journal Article %A Bachir Nail %A Abdelaziz Rabehi %A Belkacem Bekhiti %A Taha Arbaoui %T A new design of an adaptive model of infectious diseases based on artificial intelligence approach: monitoring and forecasting of COVID-19 epidemic cases %D 2020 %R 10.1101/2020.04.23.20077677 %J medRxiv %P 2020.04.23.20077677 %X Background Mathematical infectious disease models available in literature, mostly take in their design that the parameters of basic reproduction number R0 and interval serial SI as constant values during tracking the outbreak cases. In this report a new intelligent model called HH-COVID-19 is proposed, with simple design and adaptive parameters.Methods The parameters R0 and SI are adapted by adding three new weighting factors α, β and γ and two free parameters σ1 and σ2 in function of time t, thus the HH-COVID-19 become time-variant model. The parameters R0, SI, α, β, γ, σ1 and σ2 are estimated optimally based on a recent algorithm of artificial intelligence (AI), inspired from nature called Harris Hawks Optimizer (HHO), using the data of the confirmed infected cases in Algeria country in the first t = 55 days.Results Parameters estimated optimally: R0 = 1.341, SI = 5.991, α = 2.987, β = 1.566, γ = 4.998, σ1 = −0.133 and σ2 = 0.0324. R0 starts on 1.341 and ends to 2.677, and SI starts on 5.991 and ends to 6.692. The estimated results are identically to the actual infected incidence in Algeria, HH-COVID-19 proved its superiority in comparison study. HH-COVID-19 predicts that in 1 May, the infected cases exceed 50 000, during May, to reach quickly the herd immunity stage at beginning of July.Conclusion HH-COVID-19 can be used for tracking any COVID-19 outbreak cases around the world, just should updating its new parameters to fitting the area to be studied, especially when the population is directly vulnerable to COVID-19 infection.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno funding supported in this paperAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesno data availability %U https://www.medrxiv.org/content/medrxiv/early/2020/04/29/2020.04.23.20077677.full.pdf